☆ 4.2 Article

Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Outcomes of pancreatic cancer with liver oligometastasis

Tsuyoshi Takeda et al.

Summary: This study evaluated the outcomes and factors associated with overall survival of pancreatic cancer patients with liver metastasis. The results showed that oligometastasis had a more favorable overall survival compared to other types of metastases. Age, performance status, prognostic score, and serum carbohydrate antigen level were identified as significant prognostic factors. Surgical resection may provide additional survival benefits for highly selected patients.

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2023)

Add to Collection

Article Oncology

Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study

Yuta Ushida et al.

Summary: This study aimed to evaluate the characteristics of initially UR-PC cases who received modified FFX or GNP treatment. The results showed that the resection group had better overall survival, with independent prognostic factors including normalized CA19-9 concentration and tumor shrinkage after chemotherapy. Stratification according to prognostic score was useful in predicting outcomes of UR-PC cases.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice

Takuo Yamai et al.

Summary: Salvage chemotherapy for patients with unresectable pancreatic cancer who were previously treated with gemcitabine, nab-paclitaxel, 5-fluorouracil, leucovorin, and nanoliposomal irinotecan has not been fully established. This retrospective study found that the FOLFOX regimen may have limited benefits for these patients, particularly those with homologous recombination deficiency-associated gene mutations.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel

Kei Saito et al.

Summary: This study aimed to evaluate the efficacy and tolerability of S-IROX and mFFX as second-line chemotherapy for advanced pancreatic cancer patients refractory to gemcitabine plus nab-paclitaxel. The results showed that both S-IROX and mFFX were similarly tolerable and effective, with S-IROX demonstrating a favorable overall survival in patients with longer progression free survival following first-line gemcitabine plus nab-paclitaxel treatment.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

Se Jun Park et al.

Summary: The study assessed the real-world experience of nal-IRI plus 5-FU/LV in patients with advanced pancreatic cancer after gemcitabine failure, showing that this treatment option is effective with manageable toxicities.

BMC CANCER (2021)

Add to Collection

Article Oncology

Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)

Se-Il Go et al.

Summary: The study shows that using mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in significantly increased survival rates.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer Propensity Score Matching

Takafumi Mie et al.

Summary: Gemcitabine with nab-paclitaxel demonstrated higher disease control rate and lower rates of severe anorexia and diarrhea compared to modified FOLFIRINOX in our propensity-matched population study.

PANCREAS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Improved prognosis of pancreatic cancer patients with peritoneal metastasis

Tsuyoshi Takeda et al.

Summary: This study retrospectively investigated the treatment outcomes of pancreatic cancer with peritoneal metastasis, showing that the prognosis has significantly improved over time with the introduction of GnP and mFFX. Patients treated with GnP or mFFX exhibited higher objective response rates, disease control rates, and longer overall survival compared to other regimens. Performance status, neutrophil to lymphocyte ratio, and extent of peritoneal metastasis were identified as independent prognostic factors for overall survival.

PANCREATOLOGY (2021)

Add to Collection

Article Oncology

Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer

Takafumi Mie et al.

Summary: This study retrospectively analyzed the outcomes and prognostic factors of patients with unresectable pancreatic cancer receiving erlotinib plus gemcitabine therapy, showing limited efficacy, especially in terms of progression-free survival. More effective third-line treatment options are needed in the future.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer

Kenji Ikezawa et al.

Summary: In this retrospective study of 76 patients with metastatic pancreatic adenocarcinoma who failed GnP treatment, mFOLFIRINOX as a second-line chemotherapy showed significantly better objective response rates and progression-free survival compared to S-1. However, mFOLFIRINOX was associated with higher incidence of adverse events, and its use was identified as an independent factor for favorable progression-free survival on multivariate analyses, suggesting it as a promising treatment option for patients with GnP failure.

JGH OPEN (2021)

Add to Collection

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Oncology

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Masashi Sawada et al.

BMC CANCER (2020)

Add to Collection

Article Oncology

nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients

Makoto Ueno et al.

CANCER MEDICINE (2020)

Add to Collection

Article Oncology

A phase II study of modified FOLFIRINOX for chemotherapy-na < ve patients with metastatic pancreatic cancer

Masato Ozaka et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article

Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer

Tomohiro Kondo et al.

Oncotarget (2018)

Add to Collection

Article Oncology

Multicenter phase. trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

Moon Jae Chung et al.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

Hideki Ueno et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang-Gillam et al.

LANCET (2016)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology of pancreatic cancer

Milena Ilic et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Article Oncology

Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

Takuji Okusaka et al.

CANCER SCIENCE (2014)

Add to Collection

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Nutrition & Dietetics

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

Donald C. McMillan

PROCEEDINGS OF THE NUTRITION SOCIETY (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.